A5037888163- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Eosinophilic Disorders and Syndromes
- Kruppel-like factors research
- Analytical Chemistry and Chromatography
- Dermatology and Skin Diseases
- Contact Dermatitis and Allergies
- Glycosylation and Glycoproteins Research
- Skin Protection and Aging
- Acne and Rosacea Treatments and Effects
- Natural product bioactivities and synthesis
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Lung Cancer Treatments and Mutations
- Trace Elements in Health
- DNA and Nucleic Acid Chemistry
- Advanced biosensing and bioanalysis techniques
- Microfluidic and Capillary Electrophoresis Applications
- Proteoglycans and glycosaminoglycans research
- Occupational and environmental lung diseases
- Carcinogens and Genotoxicity Assessment
Centre Hospitalier Universitaire de Nîmes
2011-2024
Université de Nîmes
2007-2024
Université de Montpellier
2018-2024
Institut de Cancérologie de Bourgogne
2017-2023
Isdin (Spain)
2023
Centre Hospitalier Universitaire de Montpellier
2006-2019
Bioderma (France)
2012-2018
Wroclaw Medical University
2013
Inserm
2009
Centre National de la Recherche Scientifique
2002-2004
IMPORTANCE Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival.Fedratinib, JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF early-phase trials.OBJECTIVE To evaluate the efficacy safety of fedratinib therapy primary or secondary (post-polycythemia vera post-essential thrombocythemia) MF.DESIGN, SETTING, AND PARTICIPANTS...
Hyperuricemia and tumor lysis syndrome are well-known complications during induction treatment of aggressive non-Hodgkin's lymphomas (NHLs). Usual prophylaxis hyperuricemia consist hydration, alkalinization, administration allopurinol. This study was designed to evaluate the efficacy safety rasburicase (recombinant urate oxidase) in adult patients with NHL their first cycle chemotherapy.A total 100 from Groupe d'Etude des Lymphomes de l'Adulte centers, diffuse large B-cell lymphoma (n = 79);...
In this paper, a DNA aptamer, known to bind stereospecifically the d-enantiomer of an oligopeptide, i.e., arginine-vasopressin, was immobilized on chromatographic support. The influence various parameters (such as column temperature, eluent pH, and salt concentration) l- d-peptide retention investigated in order provide information about binding mechanism then define utilization conditions aptamer column. results suggest that dehydration at interface, charge−charge interactions, adaptive...
Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate- or high-risk myelofibrosis (MF) who were resistant intolerant to prior ruxolitinib per investigator assessment. Patients received 400 mg/day 28-day cycles. outcomes initially reported using a last-observation-carried forward (LOCF) analysis "Per Protocol" population. This updated of employs intention-to-treat principles without LOCF for all treated...
Abstract BLyS and APRIL share two receptors – transmembrane activator calcium modulator cyclophilin ligand interactor (TACI) B‐cell maturation antigen (BCMA) binds to a third receptor, BAFF‐R. We previously reported that TACI gene expression is good indicator of BLyS‐binding receptor in human multiple myeloma cell lines (HMCLs), unlike BCMA, which expressed by all HMCLs or BAFF‐R typically not late‐stage B cells. hypothesised link between through syndecan‐1, similar the situation for FGF...
BackgroundThe present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens disease progression in multiple myeloma (MM) patients.Patients MethodsAdult patients initiating any new MM therapy from October 2010 2012 were eligible. A multistage patient/site recruitment model was applied minimize the selection bias; enrollment stratified by country, region, practice type. The patient medical features, history, remission status recorded...
Summary Fedratinib, an oral Janus kinase‐2 (JAK2) inhibitor, reduces splenomegaly and improves symptom burden in patients with myelofibrosis. Regulatory approval of fedratinib 400‐mg daily was based on results updated analysis the pivotal phase III, placebo‐controlled JAKARTA trial JAK‐inhibitor‐naïve At week 24, spleen volume response rate 47% 40% 400 mg, versus 1% 9% respectively, placebo. Common adverse events were diarrhoea, nausea, anaemia, vomiting. No Wernicke encephalopathy occurred...
Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, typically associated with disease-related symptoms, splenomegaly, cytopenias and bone marrow fibrosis. Patients experience significant symptom burden reduced life expectancy. MF receive ruxolitinib as the current standard of care, but depth durability responses percentage patients achieving clinical outcome measures are limited; thus, unmet medical need exists. Pelabresib an investigational small-molecule bromodomain extraterminal...
Recently, we described the use of a DNA aptamer as new target-specific chiral stationary phase (CSP) for separation oligopeptide enantiomers (Michaud, M.; Jourdan, E.; Villet, A.; Ravel, Grosset, C.; Peyrin, E. J. Am. Chem. Soc. 2003, 125, 8672). However, from practical point view, it was fundamental to extend applicability such CSP resolution small (bioactive) molecule enantiomers. In this paper, immobilized aptamers specifically selected against D-adenosine and L-tyrosinamide were used...
Many epidemiological studies have been performed, but a potential increase in the prevalence of sensitive skin, its relationship with age and skin type impact on quality life are still debated.To answer these unresolved questions.An opinion poll was conducted representative French 5000 person sample.Fifty-nine per cent people declared very or fairly (together: skin), women (66%) more frequently than men (51.9%). The results also showed that is common (more 60%) younger (<35 years old), there...
Abstract We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) France, after a maximum follow-up five years. Patients were included according French marketing authorization 2016 (i.e. relapsed or refractory CLL previously untreated deletion 17p and/or tumor protein p53 mutations unsuitable for chemoimmunotherapy) could have initiated more than 30 days prior their enrolment retrospective...
Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue ruxolitinib due to loss response or unacceptable toxicity. Fedratinib is an oral, selective JAK2 inhibitor approved in the United States for treatment with intermediate-2 high-risk myelofibrosis. The single-arm, phase II JAKARTA2 trial assessed fedratinib 400 mg/d (starting dose) previously treated ruxolitinib. Patient-reported changes...
Abstract Background Sensitive skin usually manifests itself as unpleasant sensations and sometimes erythema. There are various triggering factors for this condition. Although sensitive may alter quality of life, its burden has not yet been explored. Objective The aim study was to develop validate a specific questionnaire called the Bo SS (Burden Skin). Methods A conceptual phase developed, followed by development phase, external validation, psychometric analysis, test–retest analysis and,...
Acne vulgaris is an inflammatory disorder of the pilosebaceous unit.To confirm that BGM (bakuchiol, Ginkgo biloba extract, and mannitol) complex increases established clinical efficacy adapalene 0.1% gel in patients with acne.A trial was conducted acne patients. A total 111 subjects received or vehicle cream for 2 months. Assessments comprised Investigator Global Assessment (IGA), global efficacy, seborrhea intensity, non-inflammatory lesions, subject perception, as well overall safety local...
LBA7006 Background: PAC is a potent JAK2 inhibitor without significant JAK1 inhibition with minimal myelosuppression in early-phase studies MF. Methods: The efficacy and safety of daily oral was compared to BAT (2:1 randomization stratified for risk platelet count). 1 0 endpoint the proportion ITT patients (pts) achieving ≥ 35% spleen volume reduction (SVR) at week (wk) 24 by centrally reviewed MRI or CT. Secondary endpoints included 50% total symptom score (TSS) wk using MPN Symptom...